(Q36475502)

14 August 2017

Randomised controlled trial of mesalazine in IBS. (English)

1 reference

14 August 2017

Michele Cicala

11

0 references

Matteo Neri

Matteo Neri

15

0 references

Massimo Bellini

Massimo Bellini

6

0 references

Fabrizio Bossa

Fabrizio Bossa

9

0 references

Rosario Cuomo

Rosario Cuomo

12

0 references

author name string

Giovanni Barbara

1

1 reference

14 August 2017

Cesare Cremon

2

1 reference

14 August 2017

Vito Annese

3

1 reference

14 August 2017

Guido Basilisco

4

1 reference

14 August 2017

Franco Bazzoli

5

1 reference

14 August 2017

Antonio Benedetti

7

1 reference

14 August 2017

Luigi Benini

8

1 reference

14 August 2017

Paola Buldrini

10

1 reference

14 August 2017

Bastianello Germanà

13

1 reference

14 August 2017

Paola Molteni

14

1 reference

14 August 2017

Marcello Rodi

16

1 reference

14 August 2017

Alfredo Saggioro

17

1 reference

14 August 2017

Maria Lia Scribano

18

1 reference

14 August 2017

Maurizio Vecchi

19

1 reference

14 August 2017

Giorgio Zoli

20

1 reference

14 August 2017

Roberto Corinaldesi

21

1 reference

14 August 2017

Vincenzo Stanghellini

22

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 December 2014

1 reference

14 August 2017

1 reference

14 August 2017

65

1 reference

14 August 2017

1

1 reference

14 August 2017

82-90

1 reference

The placebo response in medicine: minimize, maximize or personalize?

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Intestinal microbiota in functional bowel disorders: a Rome foundation report

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

The immune system in irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Association of TNFSF15 polymorphism with irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Guidelines for the management of inflammatory bowel disease in adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Postinfectious irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Role for protease activity in visceral pain in irritable bowel syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Design of treatment trials for functional gastrointestinal disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Functional bowel disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Irritable bowel syndrome: toward an understanding of severity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

The MOS 36-ltem Short-Form Health Survey (SF-36)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood

28 June 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Two randomized trials of linaclotide for chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308188

Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717362

Quality of life in persons with irritable bowel syndrome: development and validation of a new measure

21 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25533646

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25533646

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/GUTJNL-2014-308188

1 reference

release_a6mu6ccz7fae3dhti45q5zlxxq

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a6mu6ccz7fae3dhti45q5zlxxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

14 August 2017

1 reference